Despite Paclitaxel Warnings, Physicians Endorse Boston Sci’s Eluvia Stent For NTAP In CMS Pay Proposal Comments
Cardiologists and radiologists spoke in support of new technology add-on payments for Boston Scientific’s Eluvia drug-eluting stent, used to treat patients with peripheral artery disease, in comments on the US Medicare agency's Inpatient Prospective Payment System (IPPS) rule for 2020, despite concerns about paclitaxel-coated stents discussed at a late June US FDA Advisory Committee meeting.
You may also be interested in...
The US Medicare agency has been scrutinizing two new devices that have generated some buzz within the industry for pass-through payment status under its proposed 2020 Outpatient Prospective Payment System (OPPS) rules. The devices are Procept BioRobotic’s AquaBeam System for removal of prostate tissue in men with urinary tract symptoms, and Boston Scientific’s Eluvia drug-eluting stent for treatment of peripheral artery disease.
Boston Scientific Corp. posted revenue gains across its varied product categories, helped by strong performance in emerging markets.
A two-day US FDA advisory committee meeting this week yielded plenty of discussion about the apparent mortality risk tied to paclitaxel-coated balloons and stents, but few definitive conclusions.